Compare ADMA Biologics Inc (ADMA) vs HCA Health Inc (HCA) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ADMA Biologics Inc vs HCA Health Inc — how do they compare? ADMA Biologics Inc trades at $9.22 (market cap $2.13B), while HCA Health Inc trades at $408.21 (market cap $93.86B). The key difference: HCA Health Inc is far larger — about 44.1× ADMA Biologics Inc's market cap, and HCA Health Inc pays a 0.74% dividend while ADMA Biologics Inc pays none. Which is the better fit depends on your goals.
| ADMA | HCA | |
|---|---|---|
Market Cap | $2.13B | $93.86B |
Sector | Health | Health |
52-Week High | $20.38 | $545.13 |
52-Week Low | $7.60 | $334.32 |
Enterprise Value | $2.20B | $142.77B |
Dividend Yield | — | 0.74% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADMA trades at $9.16, up 2.35% today, with a bullish technical signal from moving averages and oscillators. The company reported strong profitability with a 32.43% net income margin and 43.3% ROE for 2025, though recent EPS results were mixed. Analyst consensus is strongly bullish with an $19.00 price target, but multiple class action lawsuits filed in July 2026 alleging securities fraud create significant near-term uncertainty.
The stock offers substantial upside to analyst targets if legal challenges are resolved favorably, supported by robust fundamentals and projected cash flow growth. Primary risks include the outcome of ongoing litigation and potential reputational damage. Investors should weigh strong financial performance against elevated legal and sentiment risks before establishing a position.
HCA Healthcare trades at $423.11, up 3.07% with strong technical momentum and bullish analyst sentiment. The stock shows robust fundamentals with revenue growth to $75.6B in 2025 and consistent earnings beats. Recent news highlights capacity expansion and gene therapy advancements. Technical indicators suggest bullish trends, though RSI signals potential overbought conditions near-term.
Outlook remains positive given earnings momentum and strategic investments, but risks include high debt levels and healthcare regulatory pressures. Analyst consensus targets $493 with 65% buy ratings, indicating upside potential from current levels amid manageable execution risks.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ADMA Biologics Inc
ADMA Biologics is a biopharmaceutical company specializing in plasma-derived therapies for immunodeficient patients. Key products like ASCENIV and BIVIGAM treat primary humoral immunodeficiency and help prevent infectious diseases.
Read more on ADMA →About HCA Health Inc
HCA Healthcare is a Nashville-based healthcare provider organization operating the largest collection of acute-care hospitals in the U.S. As of December 2021, the firm owned and operated 182 hospitals, 125 freestanding outpatient surgery centers, and a broad network of physician offices, urgent care clinics, and freestanding emergency rooms across nearly 20 states and a small foothold in England.
Read more on HCA →
